We analyzed the available evidence and found that when obese adults lose weight using tirzepatide, about 40% of the weight lost comes from lean tissue, which is higher than what is typically seen with dieting alone [1]. This suggests that tirzepatide may lead to a greater proportion of muscle and other lean mass being lost compared to weight loss from dietary changes alone. What we’ve found so far is based on one assertion supported by 64.0 studies or data points, with no studies or claims contradicting it. However, we note that this single assertion does not include details about how the lean mass loss was measured, how long the studies lasted, or whether the participants were matched for age, activity level, or protein intake — all of which can influence lean mass changes. We also don’t have direct comparisons showing exactly how much lean mass is lost with dieting alone in the same population, so we can’t say how large the difference truly is. The evidence we’ve reviewed leans toward the idea that tirzepatide results in more lean tissue loss relative to total weight lost, but we don’t yet know if this is due to the drug itself, the speed of weight loss, or other factors. Without more detailed studies comparing tirzepatide to dieting under controlled conditions, we can’t say whether this difference is meaningful for long-term health or strength. If you’re considering tirzepatide for weight loss, it may help you lose weight faster, but you might also lose more muscle along with fat. To protect lean mass, combining it with strength training and adequate protein intake could help — but more research is needed to confirm how best to manage this.